于2025年11月25日，鑫苑科技(本公司的全资附属公司)与郑州航美订立了资产抵偿协议3号，郑州航美 同意按人民币375.96万元的总代价向鑫苑科技转让(并促使其附属公司转让(如适用))标的物业3组。代价 将透过抵销郑州航美欠付鑫苑科技的相关金额的未偿还应收账款偿付。 智通财经APP讯，鑫苑服务(01895)发布公告，于2025年11月25日，鑫苑科技(本公司的全资附属公司)与 鑫苑地产同系公司1组订立了资产抵偿协议1号，鑫苑地产同系公司1组同意按人民币8907.31万元的总代 价向鑫苑科技转让(并促使其各自的附属公司转让(如适用))标的物业1组。代价将透过(其中包括)抵销预 付款偿付。 于2025年11月25日，鑫苑科技(本公司的全资附属公司)与天津鑫苑订立了租赁协议，内容有关租用租赁 物业，为期20年。租金将透过抵销天津鑫苑欠付鑫苑科技的相关金额的未偿还应收账款偿付。 于2025年11月25日，鑫苑科技(本公司的全资附属公司)、北京鑫苑弘晟(本公司的全资附属公司)与鑫苑 地产同系公司2组订立了资产抵偿协议2号，鑫苑地产同系公司2组同意按人民币4107万元的总代价向鑫 苑科技及北京鑫苑弘晟转让(并促使其各自 ...

Group 1 - Xinyuan Service (01895) announced asset compensation agreements on November 25, 2025, involving the transfer of properties from related companies for a total consideration of RMB 89.0731 million and RMB 41.07 million [1][2] - Xinyuan Technology, a wholly-owned subsidiary, entered into three asset compensation agreements, with the third agreement involving a transfer for RMB 3.7596 million [1] - The consideration for these agreements will be settled through offsets against prepayments and outstanding receivables [1] Group 2 - On November 25, 2025, Xinyuan Technology signed a 20-year lease agreement with Tianjin Xinyuan, with rent payments also settled through offsets against outstanding receivables [2] - The company expressed concerns regarding Xinyuan Real Estate Holdings' liquidity issues and ongoing litigation, indicating that cash repayment of prepayments and receivables is unlikely in the short term [2] - Further legal actions against Xinyuan Real Estate Holdings may incur legal costs without guaranteeing effective recovery of the amounts owed [2]

Core Viewpoint - Fosun Pharma is planning to transfer 100% equity of Shanghai Clone to enhance focus on core business and improve asset operation efficiency [1][2] Group 1: Transaction Structure - Fosun Pharma's subsidiary, Fosun Pharma Industry, will establish a special fund with a total planned fundraising of RMB 547 million, with contributions from various parties [1] - The fund will have Fosun Pharma Industry holding 9.98%, Hongyi Tianjin holding 0.18%, and Zhonghui Life holding 89.84% of the fund's assets [1] - The investment will be accounted for as other non-current financial assets at fair value after the fund is established [1] Group 2: Asset Transfer Details - Following the establishment of the special fund, Fosun Pharma Industry will transfer its 100% equity in Shanghai Clone for a total consideration not exceeding RMB 1.256 billion [2] - The main asset of Shanghai Clone includes state-owned land use rights and property ownership located at 1289 Yishan Road, Xuhui District, Shanghai, covering an area of 19,944 square meters with a building area of 45,238.55 square meters [2] - After the transfer, the group will no longer hold equity in Shanghai Clone but will continue to lease part of the property for operations, with Shanghai Fushun providing asset management services [2]